Talk to the Veterans Crisis Line now
An official website of the United States government
Search | Search by Center | Search by Source | Keywords in Title
Hurtado JG, Erickson AJ, Mitchell MN, Martin JL, Alessi CA, Dzierzewski JM, Ghadimi S, Der-Mcleod E, Perdomo C, Naeem S, Moore AA, Badr MS, Zeidler M, Fung CH. Perceived Pain Following Hypnotic Deprescribing in Older Adults. Journal of the American Geriatrics Society. 2026 Mar 1; 74(3):669-675, DOI: 10.1111/jgs.70273.
Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects. BACKGROUND: Older adults with chronic insomnia often use benzodiazepine receptor agonists (BZRAs) despite known associated risks and non-pharmacological alternatives such as cognitive behavioral therapy for insomnia (CBTI). CBTI reduces insomnia severity and could potentially improve other outcomes such as the impact of pain on daily activities, even when BZRAs are deprescribed. Yet concerns that deprescribing may worsen pain (which is often comorbid with insomnia) can be a barrier to engagement in BZRA deprescribing. This study examined changes in pain outcomes associated with deprescribing BZRAs in the context of concurrent CBTI. METHODS: Secondary data analysis was conducted using data from a randomized clinical trial that successfully decreased BZRA use in older adults. Participants (n? = 188), who were largely older (68%? = 65?years, 55? = range? = 91) and male (65%), completed CBTI concurrently with a deprescribing intervention (blinded encapsulated BZRA taper or open pill cutter taper). Participants completed the Brief Pain Inventory (BPI) at baseline, one week posttreatment (1?WK), and at a six-month (6?M) follow-up. Analyses included mixed effects models among all participants and a subset aged 65+ as well as comparison of model results to minimal clinically important difference (MCID) thresholds. RESULTS: Mixed effects models demonstrated that pain severity did not change significantly over time, broadly or in participants aged = 65?years. Significant reductions in pain interference in day-to-day living at 1?WK were observed broadly, although these reductions did not meet the MCID threshold and were no longer significant at 6?M follow-up. CONCLUSIONS: Combined BZRA deprescribing and CBTI did not meaningfully worsen pain in older adults. These results highlight the opportunity for using a combination of CBTI and deprescribing methods in patients with insomnia and comorbid pain, as well as a need for additional interventions to specifically address pain in older adults with chronic insomnia.
